Revelation Biosciences (REVBW) Stock: Why It's Up Today
Updated Oct 20, 2026, 4:00 PM ET · closing price
- Closed at $0.01, +13.33% vs the prior close of $0.01.
- Volume 7.03K shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)
REVBW jumps 13.3% to $0.01. Closed at $0.01, +13.33% vs the prior close of $0.01. Day range $0.01–$0.01, opened at $0.01.
REVBW daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 20, 2026 — REVBW jumps 13.3% to $0.01
- Closed at $0.01, +13.33% vs the prior close of $0.01. Day range $0.01–$0.01, opened at $0.01.
- Volume was 7.03K shares, 1.3x its 50-day average of 5.33K.
- 52-week range $0.01–$0.01; today's close sits at 97% of that range, 1.2% below the 52-week high.
REVBW bull case vs bear case (from the data)
- No clear positive signal in the price trend, filings or insider data right now.
- Latest fiscal-year net income: loss of $8.91M.
- Share count up 134.4% in a year (dilution).
- High volatility: average daily move of 13.3% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
REVBW latest news & SEC filings
Every SEC filing by or about REVBW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 19, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$3.32M (prior year -$2.44M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.87 (prior year -$28.04) (loss narrowed vs Jun 30, 2025)
Jul 13, 2026 · Form 8-A12B — 8-A12B filing
8-A12B filing
Jul 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.03 — Change to shareholder rights.
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jun 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade REVBW
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 13.33% (largest 13.3%). That is a volatile stock.
- Liquidity: about 6.18K shares (≈$53) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.01 vs a range of $0.01–$0.01 (97% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Aug 19, 2026; 8-K Aug 6, 2026; 10-Q Aug 6, 2026.
- Share count: 3.98M shares outstanding (Aug 3, 2026), +134.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
REVBW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | 0.01 | 0.01 | 0.01 | 0.01 | 7.03K |
| Oct 15, 2026 | 0.01 | 0.01 | 0.01 | 0.01 | 5.33K |
About Revelation Biosciences
Revelation Biosciences (REVBW) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1810560.
REVBW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jennifer Carver | Director | Aug 18, 2026 |
| Lakhmir S Chawla | Director | Aug 18, 2026 |
| Jess Roper | Director | Aug 18, 2026 |
| James Rolke | Chief Executive Officer | Aug 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James Rolke | Chief Executive Officer | Aug 18, 2026 |
| Chester Stanley Iii Zygmont | Chief Financial Officer | Aug 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
REVBW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-8.91M | -23.95 | $-8.27M |
| Dec 31, 2024 | — | $-15.04M | -1,052.16 | $-18.32M |
| Dec 31, 2023 | — | $-120.25K | -8.44 | $-7.29M |
| Dec 31, 2022 | — | $-10.83M | -149.20 | $-11.22M |
| Dec 31, 2021 | — | $-11.99M | -42.50 | $-11.09M |
Latest balance sheet: total assets $12.50M, total liabilities $2.43M, cash $11.48M (as of Jun 30, 2026).
REVBW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | — |
| May 7, 2026 | 8-K Item 2.02 (results) | — |
| Feb 26, 2026 | 8-K Item 2.02 (results) | — |
| Nov 6, 2025 | 8-K Item 2.02 (results) | — |
| Aug 8, 2025 | 8-K Item 2.02 (results) | — |
| May 8, 2025 | 8-K Item 2.02 (results) | — |
| Mar 6, 2025 | 8-K Item 2.02 (results) | — |
| Nov 8, 2024 | 8-K Item 2.02 (results) | — |
| Aug 9, 2024 | 8-K Item 2.02 (results) | — |
| May 10, 2024 | 8-K Item 2.02 (results) | — |
| Mar 22, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)United Therapeutics (UTHR)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Space Exploration Technologies (SPCX)Tesla (TSLA)Sandisk (SNDK)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on REVBW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 20, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.